Actinium Pharmaceuticals, Inc (ATNM)
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing targeted cancer therapies using its proprietary Antibody-Radionuclide Conjugate (ARC) platform. The company specializes in creating treatments for hematologic malignancies and other cancers, leveraging its expertise in radiolabeled antibody technology to deliver targeted radiation directly to cancer cells.
Company News
A new market research report reveals targeted alpha therapies (TAT) for cancer treatment are projected to grow from $199.6 million in 2024 to $1.1 billion by 2030, with a 44% CAGR, driven by precision medicine and unmet oncology treatment needs.
Here is how Actinium Pharmaceuticals (ATNM) and Encompass Health (EHC) have performed compared to their sector so far this year.
A more selective small-cap index has consistently outperformed the Russell 2000
Upgrades According to Morgan Stanley, the prior rating for First Solar Inc (NASDAQ:FSLR) was changed from Underweight to Equal-Weight. For the second quarter, First Solar had an EPS of $1.89, compared to year-ago quarter EPS of $0.52. At the moment, the stock has a 52-week-high of $232.00 and a 52-week-low of $115.66. First Solar closed at $186.4...